Online Meeting for Adults with CAH – 3rd February 2024, 10:30-12:30 UK time
This is an opportunity to meet other adults with CAH in a safe and supportive environment, where we share experiences, learn about current developments and have the opportunity to socialise with others in the CAH community.
We’re pleased to announce that we’ll be joined by Dr. Velusamy Anand who will present on some exciting new clinical research taking place in the UK looking at new treatment for CAH.
The meeting will be held over Microsoft Teams from 10:30 to 12:30 UK time on 3rd February 2024.
If you’d like to attend, contact Kaz via our Meet the team page.
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...